5:50 PM
 | 
Sep 08, 2009
 |  BC Extra  |  Clinical News

Osiris falls on Prochymal miss

Osiris Therapeutics Inc. (NASDAQ:OSIR) fell $4.18 (34%) to $8.03 on Tuesday after IV Prochymal missed the primary endpoints in two double-blind, international Phase III trials to treat acute graft-versus-host disease (GvHD). Preliminary data from a trial in 260 patients showed that...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >